NICE | GenomeWeb


The NICE recommendation specifies the use of Oncotype DX for intermediate risk patients for whom doctors are unclear whether to prescribe chemotherapy.

In order to keep the therapies in the fund, drugmakers will have to meet a cost and clinical efficacy threshold. NHS will also offer companies the chance to provide their treatments at a discount to meet the cost threshold.

NEW YORK (GenomeWeb News) – What were the articles that gained the most interest from GenomeWeb Daily News' readers last week? Here are the top five:

The UK's National Institute for Health and Clinical Excellence has released a draft update to its guidelines for familial breast cancer testing, screening, and treatment.

As regulators and payors around the world are demanding more evidence that healthcare products improve patient outcomes and save money, Roche this week attempted to reassure investors that its strategy to develop innovative products — with a strong focus on molecularly guided per

After a survey of UK oncologists revealed that access hurdles and high costs associated with biomarker testing are limiting their ability to prescribe personalized treatments, Merck Serono has issued a "call to action" for the government and pharmaceutical industry to work togeth


Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.